Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
$SUPN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
674
Website
SUPN Metrics
BasicAdvanced
$2.1B
30.34
$1.11
0.74
-
Price and volume
Market cap
$2.1B
Beta
0.74
52-week high
$40.28
52-week low
$27.05
Average daily volume
753K
Financial strength
Current ratio
2.44
Quick ratio
2.162
Long term debt to equity
2.558
Total debt to equity
3.134
Profitability
EBITDA (TTM)
138.656
Gross margin (TTM)
88.42%
Net profit margin (TTM)
9.27%
Operating margin (TTM)
8.77%
Effective tax rate (TTM)
32.55%
Revenue per employee (TTM)
$990,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
6.32%
Valuation
Price to earnings (TTM)
30.335
Price to revenue (TTM)
2.783
Price to book
1.82
Price to tangible book (TTM)
4.57
Price to free cash flow (TTM)
11.382
Free cash flow yield (TTM)
8.79%
Free cash flow per share (TTM)
295.03%
Growth
Revenue change (TTM)
11.82%
Earnings per share change (TTM)
-464.25%
3-year revenue growth (CAGR)
3.57%
10-year revenue growth (CAGR)
19.52%
3-year earnings per share growth (CAGR)
-5.56%
10-year earnings per share growth (CAGR)
24.45%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
Bulls say / Bears say
Supernus Pharmaceuticals' acquisition of Sage Therapeutics for up to $795 million grants access to Zurzuvae, the only U.S.-approved postpartum depression pill, potentially expanding its market presence and revenue streams. (reuters.com)
The company's Qelbree® product saw a 97% increase in net sales to $46.4 million in Q4 2023 compared to Q4 2022, indicating strong market adoption and growth potential. (biospace.com)
Supernus reported a free cash flow to the firm of $66.85 million in Q1 2025, up 1.0% quarter-over-quarter, demonstrating solid cash-generation capacity and financial stability. (marketbeat.com)
In Q1 2025, Supernus reported a net loss of $11.83 million and an operating loss of $10.26 million, indicating profitability challenges. (marketbeat.com)
The company's EBITDA margin declined to 9.0% in Q1 2025 from 25.6% in Q4 2024, signaling margin pressure and potential operational inefficiencies. (marketbeat.com)
Supernus' SG&A expenses consumed approximately 60.0% of revenue in Q1 2025, which could weigh on operating profitability and indicate high operational costs. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
SUPN News
AllArticlesVideos
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·2 weeks ago
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·1 month ago
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $2.1B as of July 28, 2025.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 30.34 as of July 28, 2025.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.